膜杰作
Star Staining
抗体来源（Source）
Anti-Rituximab Antibody (AY37) is a Mouse monoclonal antibody produced from a hybridoma created by fusing SP2/0 myeloma and Mouse B-lymphocytes.
克隆号（Clone）
AY37
种属（Species）
Mouse
亚型（Isotype）
Mouse IgG1/kappa
抗体类型（Antibody Type）
Hybridoma Monoclonal
种属反应性（Reactivity）
Human
免疫原（Immunogen）
Rituximab.
特异性（Specificity）
Recognizes Rituximab specifically, no cross reactivity with other humanized antibodies.
应用（Application）
| Application | Recommended Usage |
| ELISA | 0.6-312.5 ng/mL |
纯度（Purity）
>95% as determined by SDS-PAGE.
纯化（Purification）
Protein A purified/ Protein G purified
制剂（Formulation）
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- 4-8°C for 12 months in lyophilized state;
- -70°C for 12 months under sterile conditions after reconstitution.
电泳（SDS-PAGE）
Anti-Rituximab Antibody (AY37) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
活性（Bioactivity）-ELISA
Detection of rituximab by bridging ELISA in serum. Immobilized Anti-Rituximab Antibody (AY37) (Cat. No. RIB-Y37) at 2 μg/mL, add increasing concentrations of rituximab (10% human serum) and then add Biotinylated Anti-Rituximab Antibody (Cat. No. RIB-BY35) at 1 μg/mL. Detection was performed using HRP-conjugated streptavidin with a sensitivity of 1 ng/mL (QC tested).
Protocol
Demonstration of the specificity of Anti-Rituximab Antibody (AY37) (Cat. No. RIB-Y37) to the rituximab.
Protocol
活性（Bioactivity）-FACS
FACS analysis shows that the binding of rituximab to 293F overexpressing CD20 was inhibited by increasing concentration of Anti-Rituximab Antibody (AY37) (Cat. No. RIB-Y37). The concentration of rituximab used is 10 ng/ml. The IC50 is 0.019 μg/ml (Routinely tested).
Protocol
背景（Background）
Rituxan is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light- and heavy-chain variable region sequences and human constant region sequences. Rituximab is composed of two heavy chains of 451 amino acids and two light chains of 213 amino acids
